Tigecycline
- Generic Name
- Tigecycline
- Brand Names
- Tygacil, Tigecycline Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C29H39N5O8
- CAS Number
- 220620-09-7
- Unique Ingredient Identifier
- 70JE2N95KR
- Background
Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
- Indication
For the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, ...
- Associated Conditions
- Bacterial Infections, Community Acquired Pneumonia (CAP), Complicated Intra-Abdominal Infections (cIAIs), Complicated Skin and Skin Structure Infection
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.